Specialty Pharmacy

Although the majority of survey respondents will continue using telehealth, providers must ensure the safety of their software in order to maintain patient trust.

Mortality rates from non-small cell lung cancer have significantly declined in the United States in recent years.

Four new subtypes of cells within triple-negative breast cancer have been uncovered, containing promising new therapeutic targets for the disease.

Fingolimod (Gilenya), which is approved by the FDA to treat multiple sclerosis flare-ups, may also block HIV and reduce the latent reservoir.

Cancer survivors’ lean body mass found to be lower than the general population, which was connected with prior abdominal or pelvic radiation.

Vitolarsen is the second FDA-approved targeted treatment for patients with Duchenne muscular dystrophy who have a confirmed mutation of the gene that is amenable to exon 53 skipping.

Like so many other conferences and events, ASCO transitioned to an online format because of the coronavirus disease 2019 (COVID-19) outbreak.

Study shows significant genomic differences between tumors caused by different strains of human papillomavirus.

Ozanimod (Zeposia) became the third oral S1P modulator approved by the FDA for the treatment of multiple sclerosis,

The combination of sintilimab, pemetrexed, and a platinum-based chemotherapy has shown promise for nonsquamous non-small cell lung cancer.

Human papillomavirus vaccine may reduce the chance of high-grade cervical intraepithelial neoplasis.

Frontline health care workers have a 3-fold increased risk of contracting coronavirus disease 2019 despite use of personal protective equipment.

Study shows that an individual's response to immunotherapy can be predicted within weeks, based on increasing or decreasing levels of circulating tumor DNA.

By using a non-invasive screening model, care providers can help catch and treat more cases of colorectal cancer, a new study suggests.

Study examines the effect of a low-calorie, plant-based diet combined with vitamin C in helping to kill cancer cells.

Cancer care providers have increasingly been using biosimilars on a case-by-case basis with patients.

Belantamab mafodotin-blmf is the first anti-BCMA therapy approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma who received at least 4 prior therapies.

Introducing an online PharmD program presents a unique set of challenges for educators.

JD Power 2020 US Pharmacy Study ranks Good Neighbor Pharmacy highest among brick-and-mortar chain drug store pharmacies in customer satisfaction.

Women comprise more than 60% of pharmacy graduates, yet gender gaps still exist in pharmacy ownership, school deanships, and other leadership positions.

With the groundbreaking advancements in specialty pharmacy, it is important to recognize the uniqueness of these medications and their respective patient populations.

Although transfering the annual event to a virtual format presented challenges, NASP President and CEO Sheila Arquette, RPh, said she is excited to connect with attendees just as much as in previous years.

Research may address the lack of effective treatments for mental fatigue among patients with multiple sclerosis.

This year’s annual NASP meeting will feature an enhanced virtual environment that allows attendees to earn required CPE credits, share best practices, and browse a convention hall.

Home infusion of teprotumumab-trbw (Tepezza), a breakthrough treatment for thyroid eye disease, was found to effectively minimize the chance of infection with coronavirus disease 2019 for both patients and staff of Chartwell Pennsylvania, LP.

In the United States, these findings would translate to more than 269,000 prevented breast cancer cases and nearly 44,000 prevented cases of ovarian cancer.

As more Americans identify as LGBTQIA+, an effort needs to made to educate pharmacists on LGBTQIA+ health and culture.

Representatives from the organizations spoke with HHS last week before President Donald Trump signed several executive orders, including one that would address manufacturer rebates also collected by PBMs.

Officials with the FDA have approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.

Pharmacists, researchers, and other health care professionals must keep pushing these boundaries to continue advancing the field of medicine and providing effective patient care.